Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many general statements are not supported by the provided label excerpts (e.g., pregnancy category system, specific studies, fetal growth restriction). Some mechanism/clinical benefits and transmission-prevention claims are also not verifiable from the supplied label text.
Category Scores
Accurate Statements
Acyclovir is indicated for the treatment of genital herpes.
INDICATIONS AND USAGE: “Acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.”
Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
USE IN SPECIFIC POPULATIONS (Pregnancy): “Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
Acyclovir Oral Suspension is intended for oral ingestion only.
WARNINGS: “Acyclovir Oral Suspension is intended for oral ingestion only.”
Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.
CONTRAINDICATIONS: “Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.”
Acyclovir should be administered to a nursing mother with caution and only when indicated.
USE IN SPECIFIC POPULATIONS (Nursing Mothers): “Acyclovir should be administered to a nursing mother with caution and only when indicated.”
Unsupported Statements
Acyclovir is an antiviral medication used to treat herpes simplex virus (HSV) infections.
The provided label excerpts include indications for genital herpes (HSV) and other herpes viruses, but the claim is a broad characterization not explicitly stated in the provided excerpts as written.
Acyclovir works by stopping the replication of the herpes simplex virus.
No mechanism statement is present in the provided excerpts.
Acyclovir is available in oral, topical, and intravenous forms.
The provided label excerpts describe oral suspension and mention intravenous acyclovir in a drug interaction statement; no provided excerpts support “topical” availability.
Animal studies have shown that acyclovir can cause birth defects in rats and mice.
No animal teratogenicity/birth-defects statement appears in the provided label excerpts.
The animal studies were conducted at high doses.
No animal-study dosing description is present in the provided label excerpts.
Human studies have been limited.
No statement about the extent/limitations of human studies is present in the provided label excerpts.
Human studies suggest that acyclovir is safe during pregnancy.
The provided pregnancy excerpt uses a benefit-vs-risk framing; it does not state “safe during pregnancy.”
A study published in the Journal of Infectious Diseases found that acyclovir was not associated with an increased risk of birth defects in pregnant women with HSV.
No specific journal study or birth-defect risk conclusion is present in the provided label excerpts.
The FDA has classified acyclovir as a category B medication.
No pregnancy category (e.g., Category B) statement is present in the provided label excerpts.
FDA notes that animal studies have shown some risk for category B medications.
No pregnancy category framework or related FDA wording appears in the provided label excerpts.
FDA notes that human studies have not shown risk for category B medications.
No pregnancy category framework or related FDA wording appears in the provided label excerpts.
FDA notes that the benefits of acyclovir may outweigh the risks in pregnant women with HSV.
The provided excerpt states a conditional use instruction (“should be used… only if the potential benefit justifies the potential risk”); it does not specifically state “benefits may outweigh the risks in pregnant women with HSV.”
Some studies have suggested that acyclovir may be associated with fetal growth restriction.
No fetal growth restriction statement is present in the provided label excerpts.
More research is needed to confirm the association between acyclovir and fetal growth restriction.
No fetal growth restriction discussion is present in the provided label excerpts.
Pregnant women with HSV are at risk of transmitting the virus to their baby, which can lead to neonatal herpes.
No transmission-to-neonate or neonatal herpes statement is present in the provided label excerpts.
Acyclovir can reduce the risk of transmitting HSV to the baby.
No transmission-reduction claim is present in the provided label excerpts.
Acyclovir can prevent severe complications such as encephalitis and disseminated HSV.
No prevention-of-specific-complications statement is present in the provided label excerpts.
Acyclovir can improve quality of life for pregnant women with HSV by reducing symptoms and preventing outbreaks.
No quality-of-life statement and no pregnancy-specific symptom/outbreak prevention claim is present in the provided label excerpts.
Pregnant women with HSV should not stop taking acyclovir without consulting their healthcare provider, as this can lead to severe complications.
No patient-advice statement about stopping therapy is present in the provided label excerpts.
Acyclovir is generally considered safe during breastfeeding.
The provided nursing excerpt instructs caution and “only when indicated”; it does not state “generally considered safe.”
Contradictions
Low
AI Statement
Acyclovir is available in oral, topical, and intravenous forms.
Label Reference
WARNINGS: “Acyclovir Oral Suspension is intended for oral ingestion only.”; DRUG INTERACTIONS: “Coadministration of probenecid with intravenous acyclovir…” (mentions IV but does not mention topical).
Low
AI Statement
Human studies suggest that acyclovir is safe during pregnancy.
Label Reference
USE IN SPECIFIC POPULATIONS (Pregnancy): “Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
Low
AI Statement
Acyclovir is generally considered safe during breastfeeding.
Label Reference
USE IN SPECIFIC POPULATIONS (Nursing Mothers): “Acyclovir should be administered to a nursing mother with caution and only when indicated.”
Important Omissions
For the treatment of herpes simplex virus specifically, the provided label excerpts only explicitly cover genital herpes; there is no explicit support provided for “HSV infections” broadly (e.g., oral HSV/herpes simplex outside genital herpes).
Importance:
Moderate
No dosing, renal impairment adjustment, or dialysis guidance is mentioned in the AI claims despite dosage being central for administration safety.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several pregnancy/breastfeeding safety assertions are overstated relative to the label excerpt’s benefit-vs-risk and caution language. Additional claims about neonatal transmission and preventing severe complications are unsupported by the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Multiple statements are not supported by the provided label excerpts, including pregnancy category (Category B), animal/human risk details, fetal growth restriction, neonatal transmission/complication prevention, and topical availability.
Suggested Improvement
Restrict claims to the provided label excerpts (e.g., pregnancy benefit-vs-risk wording; nursing caution; contraindication; oral ingestion intent; supported indications such as genital herpes) and remove unsupported specifics not present in the label.